breast cancer cells

[Nature Communications] To understand the mechanism of this bone-tropism of ER+ tumor, and to identify liquid biopsy biomarkers for patients with high risk of bone metastasis, the secreted extracellular vesicles and cytokines from bone-tropic breast cancer cells were examined.

[British Journal of Cancer] Scientists used a xenograft model of spontaneous metastasis to the liver from an ectopic tumour employing a metastatic TNBC cell line. Atorvastatin was provided to sensitise metastatic cells, followed by chemotherapy.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers developed dual-mechanism estrogen receptor (ER) inhibitors that caused alternate, noncanonical structural perturbations of the receptor ligand-binding domain to antagonize proliferation in ER-positive breast cancer cells and in allele-specific resistance models.

[Proceedings of the National Academy of Sciences of the United States of America] Investigators manipulated tripartite motif–containing 47 (TRIM47) expression in estrogen receptor–positive breast cancer cells MCF-7 and its 4-hydroxytamoxifen (OHT)-resistant derivative OHTR, which was established in a long-term culture with OHT. TRIM47 promoted both MCF-7 and OHTR cell proliferation.

[Nature Communications] The authors showed that triple inhibition with fulvestrant, CDK4/6i and AKT inhibitor durably impaired growth of breast cancer cells, prevented progression and reduced metastasis of tumor xenografts resistant to CDK4/6i-fulvestrant combination or fulvestrant alone.

[Journal of the American Chemical Society] Seven CADA compounds (CADA, VGD020, VGD071, TL020, TL023, LAL014, and DJ010) were examined for reduction of cellular sortilin expression and progranulin-induced breast cancer stem cell propagation.